ReviewJournal of orthopaedic translation2020
The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review.
Review in Journal of orthopaedic translation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy.Drug design, development and therapy · 2026Review
- Updated Advances on Drugs and Bone-Targeting Nanoparticles for Osteoporosis Therapy: Carrier Materials, Modification, Function Mechanism, and Applications-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Hypoxia Promotes Osteoclast Differentiation by Weakening USP18-Mediated Suppression on the NF-κB Signaling Pathway.International journal of molecular sciences · 2024Article
- Research trends in exercise therapy for the treatment of pain in postmenopausal osteoporosis over the past decade: A bibliometric analysis.World journal of orthopedics · 2024Article
- Role of ubiquitination in the occurrence and development of osteoporosis (Review).International journal of molecular medicine · 2024Review
- Nodakenin Ameliorates Ovariectomy-Induced Bone Loss by Regulating Gut Microbiota.Molecules (Basel, Switzerland) · 2024Article
- Linking the relation between gut microbiota and glucocorticoid-induced osteoporosis.Journal of bone and mineral metabolism · 2023Review
- The effect of drug holiday on preventing medication-related osteonecrosis of the jaw in osteoporotic rat model.Journal of orthopaedic translation · 2023Article
- Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.Journal of orthopaedic translation · 2023Article
- Fecal microbiota transplantation ameliorates bone loss in mice with ovariectomy-induced osteoporosis via modulating gut microbiota and metabolic function.Journal of orthopaedic translation · 2022Article
- Current progress and trends in musculoskeletal research: Highlights of NSFC-CUHK academic symposium on bone and joint degeneration and regeneration.Journal of orthopaedic translation · 2022Review
- A narrative review of the moderating effects and repercussion of exercise intervention on osteoporosis: ingenious involvement of gut microbiota and its metabolites.Journal of translational medicine · 2022Review
- A novel image-based machine learning model with superior accuracy and predictability for knee arthroplasty loosening detection and clinical decision making.Journal of orthopaedic translation · 2022Article
- Real-world effectiveness of osteoporosis treatments in Germany.Archives of osteoporosis · 2022Observational
- Editorial: Recent trends in pharmacological treatment of musculoskeletal disorders.Frontiers in pharmacology · 2022Article
- Mechanism and Experimental Verification ofFrontiers in endocrinology · 2022Article
- The "Three in One" Bone Repair Strategy for Osteoporotic Fractures.Frontiers in endocrinology · 2022Review
- A bibliometric research based on hotspots and frontier trends of denosumab.Frontiers in pharmacology · 2022Article
- Hydrogel contained valproic acid accelerates bone-defect repair via activating Notch signaling pathway in ovariectomized rats.Journal of materials science. Materials in medicine · 2021Article
- DANCR Mediates the Rescuing Effects of Sesamin on Postmenopausal Osteoporosis Treatment via Orchestrating Osteogenesis and Osteoclastogenesis.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to assess the efficacy and safety of denosumab therapy in osteoporotic postmenopausal women who were previously treated with bisphosphonates.
methodsMeta-analyses of four available randomised controlled trials that compared osteoporotic patients who switched to denosumab from bisphosphonates (n = 1416) and those who continued bisphosphonates therapy (n = 1411) were included.
resultsThe increase in bone mineral density (BMD) of both the spine and hip was significantly higher in patients who shifted to denosumab than in those who continued bisphosphonates. Despite the incidence of adverse events (AEs) and fractures being comparable, treatment withdrawal owing to AEs was significantly less frequent in the denosumab group.
conclusionThe outcomes and treatment compliance were improved in postmenopausal osteoporotic women who shifted to denosumab from bisphosphonates. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: The replacement of bisphosphonates with denosumab may lead to better therapeutic efficacy and fewer adherence barriers than those with continued usage of bisphosphonates, which in the future may guide the choice of drug therapy in clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.